Aileron expands into endocrine, metabolic diseases

Mass High Tech: The Journal of New England Technology

Aileron Therapeutics Inc., a Cambridge biotech founded five years ago to develop protein-based treatments for cancer, has announced it’s beginning a new program focused on drugs for endocrine and metabolic diseases.